The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: a consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

Fruchart, J.-C. et al. (2019) The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: a consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. Cardiovascular Diabetology, 18(1), 71. (doi: 10.1186/s12933-019-0864-7) (PMID:31164165) (PMCID:PMC6549355)

[img]
Preview
Text
188660.pdf - Published Version
Available under License Creative Commons Attribution.

1MB

Abstract

In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARMα agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profile. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARMα agonist safely reduces residual cardiovascular risk.

Item Type:Articles
Keywords:Atherogenic dyslipidemia, diabetes, inflammation, PROMINENT, pemafibrate (K-877), remnant cholesterol, residual cardiovascular risk, SPPARMalpha, selective peroxisome proliferator-activated receptor alpha modulator, triglycerides, visceral obesity.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Packard, Professor Chris
Authors: Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., Duriez, P., Eckel, R. H., Ezhov, M. V., Farnier, M., Ginsberg, H. N., Hermans, M. P., Ishibashi, S., Karpe, F., Kodama, T., Koenig, W., Krempf, M., Lim, S., Lorenzatti, A. J., McPherson, R., Nuñez-Cortes, J. M., Nordestgaard, B. G., Ogawa, H., Packard, C. J., Plutzky, J., Ponte-Negretti, C. I., Pradhan, A., Ray, K. K., Reiner, Ž., Ridker, P. M., Ruscica, M., Sadikot, S., Shimano, H., Sritara, P., Stock, J. K., Su, T.-C., Susekov, A. V., Tartar, A., Taskinen, M.-R., Tenenbaum, A., Tokgözoğlu, L. S., Tomlinson, B., Tybjærg-Hansen, A., Valensi, P., Vrablík, M., Wahli, W., Watts, G. F., Yamashita, S., Yokote, K., Zambon, A., and Libby, P.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:Cardiovascular Diabetology
Publisher:BioMed Central
ISSN:1475-2840
ISSN (Online):1475-2840
Copyright Holders:Copyright © 2019 The Authors
First Published:First published in Cardiovascular Diabetology 18(1):71
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record